- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
June 9, 2004
Date of Report (Date of earliest event reported)
------------
ZYMOGENETICS, INC.
(Exact name of registrant as specified in its charter)
Washington 0-33489 91-1144498
(State or other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification Number)
1201 Eastlake Avenue East
Seattle, Washington 98102-3702
(Address of principal executive offices) (Zip Code)
206-442-6600
(Registrant's telephone number, including area code)
Item 5. Other Events
On June 9, 2004, ZymoGenetics, Inc. issued a press release announcing the
receipt of a notice from Novo Nordisk exercising its extension right under an
existing option and licensing agreement which gives them the right to
exclusively license a limited number of proteins outside North America. Under
the terms of this agreement, Novo Nordisk will extend the option agreement for
two years and will pay ZymoGenetics $7.5 million each year. The press release is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits.
99.1 Press Release issued June 9, 2004 by ZymoGenetics, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
ZYMOGENETICS, INC.
Date: June 9, 2004 By: /s/ JAMES A. JOHNSON
--------------------------------
Name: James A. Johnson
Title: Senior Vice President and
Chief Financial Officer
EXHIBIT INDEX
Exhibit Document Description
Number
- ------- --------------------
99.1 Press release issued June 9, 2004 by ZymoGenetics, Inc.